New antidepressants: use in high-risk patients

This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical psychiatry Vol. 54 Suppl; p. 61
Main Author Hale, A S
Format Journal Article
LanguageEnglish
Published United States 01.08.1993
Subjects
Age Factors
Aged
Antidepressive Agents - adverse effects
Antidepressive Agents - pharmacokinetics
Antidepressive Agents - therapeutic use
Benzamides - adverse effects
Benzamides - pharmacokinetics
Benzamides - therapeutic use
Depressive Disorder - complications
Depressive Disorder - drug therapy
Depressive Disorder - psychology
Drug Interactions
Epilepsy - complications
Heart Failure - complications
Humans
Liver Failure - complications
Moclobemide
Monoamine Oxidase Inhibitors - adverse effects
Monoamine Oxidase Inhibitors - pharmacokinetics
Monoamine Oxidase Inhibitors - therapeutic use
Psychomotor Performance - drug effects
Renal Insufficiency - complications
Risk Factors
Serotonin Uptake Inhibitors - pharmacokinetics
Serotonin Uptake Inhibitors - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.
ISSN:0160-6689
1555-2101